Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that MET Exon 14 (Deletion) status confers therapeutic sensitivity to Tepotinib in patients with Non-Small Cell Lung Cancer.
The European Medicines Agency (EMA) has authorized tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
This statement is based on a regulatory approval from the European Medicines Agency:
TEPMETKO as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.